Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Excellent review! I was disappointed on the timelines, but I think solid progress is being made. I was at the meeting and I think you’re right. The meeting was well received although there is frustration that we’re not moving quicker.
It happened early today, so somebody definitely took a position.
Ed on TV
Ed Pershing talks about being CEO of $PVCT #RoseBengalSodium #RoseBengal @knoxnews https://t.co/rCcuznYI7z
— Provectus Biopharmaceuticals, Inc. (@ProvectusBio) May 18, 2024
It’s the same as before except no stock price posted.
IV is subscription based service only now.
Excellent
Ralph "Blue" Kidd
Chief Customer Liaison blue@investorvillage.com
504-250-0021
Send Blue a message
I was able to sign in on my computer and iPhone.
I agree, the current SP is down right silly, and when this takes off it will be amazing for all long term suffering investors lol
I purchased the lifetime membership several years ago when Blue was trying to raise money, but I think nine dollars is a reasonable access fee and helps support the site. As they say, nothing is free.
I just looked at the website, and the free access is no longer available.
Yes they are back up now though I’m not sure about the pay membership only. He is rolling it out as he can.
From the conclusions on the Poster.
PV-10, an IL immunotherapeutic agent, demonstrates significant anti-tumor activity in
HNSCC.
• Our In vitro studies show PV-10 induces potent ICD in HNSCC cells.
• Our In vivo experiments show IL PV-10 lead to substantial tumor regression and complete
responses in some mice.
• These findings underscore the significance of PV-10-induced ICD which may offer a novel
and promising approach for managing HNSCC and potentially pave the way for improved
survival rates and reduced adverse events
Happy Easter!
Mark 16: 1-7
Resurrection Morning
16 When the Sabbath was over, Mary Magdalene, Mary the mother of James, and Salome bought spices, so they could go and anoint Him. 2 Very early in the morning, on the first day of the week, they went to the tomb at sunrise. 3 They were saying to one another, “Who will roll away the stone from the entrance to the tomb for us?” 4 Looking up, they observed that the stone—which was very large—had been rolled away. 5 When they entered the tomb, they saw a young man dressed in a long white robe sitting on the right side; they were amazed and alarmed.
6 “Don’t be alarmed,” he told them. “You are looking for Jesus the Nazarene, who was crucified. He has been resurrected! He is not here! See the place where they put Him. 7 But go, tell His disciples and Peter, ‘He is going ahead of you to Galilee; you will see Him there just as He told you.’ ”
The Holy Bible: Holman Christian standard version. (2009). (Mk 16:1–7). Nashville: Holman Bible Publishers.
Happy Easter!
Mark 16: 1-7
Resurrection Morning
16 When the Sabbath was over, Mary Magdalene, Mary the mother of James, and Salome bought spices, so they could go and anoint Him. 2 Very early in the morning, on the first day of the week, they went to the tomb at sunrise. 3 They were saying to one another, “Who will roll away the stone from the entrance to the tomb for us?” 4 Looking up, they observed that the stone—which was very large—had been rolled away. 5 When they entered the tomb, they saw a young man dressed in a long white robe sitting on the right side; they were amazed and alarmed.
6 “Don’t be alarmed,” he told them. “You are looking for Jesus the Nazarene, who was crucified. He has been resurrected! He is not here! See the place where they put Him. 7 But go, tell His disciples and Peter, ‘He is going ahead of you to Galilee; you will see Him there just as He told you.’ ”
The Holy Bible: Holman Christian standard version. (2009). (Mk 16:1–7). Nashville: Holman Bible Publishers.
I think we are beginning to see the light at the end of the tunnel!
Updates on auctions aren’t going to move this stock, we need corporate structure updates and where MP is planning on taking the company in the future.
Hopefully, with some news, we can generate that level of volume, but not till news.
If my memory serves me correctly, they usually do provide the presentation they give at the conferences.
We had a few good days with good volume and now it’s gone again lol
Merry Christmas!
Isaiah 9:6-7
"For to us a child is born, to us a son is given, and the government will be on his shoulders. And he will be called Wonderful Counselor, Mighty God, Everlasting Father, Prince of Peace. Of the increase of his government and peace there will be no end. He will reign on David's throne and over his kingdom, establishing and upholding it with justice and righteousness from that time on and forever. The zeal of the LORD Almighty will accomplish this."
Merry Christmas!
Isaiah 9:6-7
"For to us a child is born, to us a son is given, and the government will be on his shoulders. And he will be called Wonderful Counselor, Mighty God, Everlasting Father, Prince of Peace. Of the increase of his government and peace there will be no end. He will reign on David's throne and over his kingdom, establishing and upholding it with justice and righteousness from that time on and forever. The zeal of the LORD Almighty will accomplish this."
Is this the first time that music and movies are part of the auction or have these been included before?
I attended the AM and below are my notes from the 2023 Provectus Annual Meeting.
All five directors were present in person this year.
All six proposals approved.
Dominic went over the slides that updated the progress of the company. Slides provided below but you must go past the first few pages to get to the slides. (See slides PVCT sent to investors)
After the presentation, Ed made a few comments, and one interesting remark is that PVCT is going to explore the possibility of having a conference call every 6 months to try and keep the investors more up to date on what’s happening with the company.
The 2022 Reverse Split was discussed and PRH stated that the events they hoped would be in place didn’t happen and they simply decided to not go forward with the R/S.
This is a good place to discuss the TGA event that we all thought would have triggered the R/S. I asked whether an application had been submitted to the TGA and Dominic commented that it was their policy not to comment on these types of actions by management. This is understandable based on previous actions by Dees and their public announcement that they had submitted a package to the FDA which was turned down because of the lack of significant patient data. However, there were comments from other investors in private that they had heard that PVCT had decided to not submit the package because TGA had decided that Intermittent Melanoma was not a rare disease and therefore was not eligible for being fast tracked. Consequently, management decided to not pursue this path of TGA regulatory approval and to go forward with the FDA or maybe with the normal TGA regulatory path (not sure).
There was an interesting discussion about whether or not the delays related to COVID was a blessing or a curse. Management believes that in the long run it was a blessing because it allowed them to open up many different avenues of potential RB use such as dermatology, virology, ophthalmology, and others. They believe without the COVID delays they would have gone down the oncology path and any other venues would not have been explored.
One of my biggest concerns has been funding. Dominic commented that they could go and get the money they needed at a price point that wouldn't necessarily be advantageous to the current stockholders, but that was always an option. They seemed fairly confident that they could find the money they needed to get the trials done without destroying the current stockholders' share position. The bottom line is the money that Dominic and Ed have been putting into the company was not to keep the lights on, but to progress the company's objectives towards regulatory approval by the FDA and maybe the TGA. Also of interest, there are individuals who have the ability to fund specific trials that interest them, and Ed is in discussions with them.
The question was asked regarding Bascom Palmer and negotiations for rights to use their equipment with RB to treat fungal keratitis. Many investors believed that negotiations have broken down. Dominic replied that this was definitely not the case and their relationship with Bascom Palmer was strong and that it was taking longer than anticipated because of the bureaucracy associated with the University of Miami (For Profit University) which is who Bascom Palmer is a part of. He also commented that their equipment is not what is doing the heavy lifting in treating fungal keratitis, but it is PV-10 and there are other equipment options.
A question was asked about operational costs associated with operations and trial costs and Ed commented that the company’s current spend rate is $250K per month.
In regard to the University of Tennessee’s grant for exploring PV-10 with animal sciences, Dr. Lacey stated it has taken a while to find the lead investigator for the study. However, they have now found the individual they need, and she is not only a veterinarian but also a PhD and they have every confidence in her and believe the outcome will be fruitful. In essence, the study is just now getting off the ground, but progress will be made. Unfortunately, the use of PV-10 in animal sciences in Australia will not be of much use in the study other than lessons learned from clinic use and practical applications. The lead investigator will have to start from scratch due to academic rigor although she will have the advantage of the information from the veterinarian’s use of RB in dogs (or other animals) in Australia.
The board of directors stated that they are trying to stay focused and putting everything on the back burner that is not related to their current oncology trials. They are concentrating on pancreatic cancer, metastatic uveal melanoma, stage III melanoma combo, and intransit metastatic melanoma (possibly TGA route, not sure) and will be moving forward with these trials. Also of interest, PVCT is trying to initiate PET scans in their trials because only PET scans are able to determine if the tumor is truly dead. A dead tumor may show up on a regular scan, but the Radiologist can’t tell if the tumor is dead or not and therefore won’t declare a CR without a PET scan. Regarding the date of conclusion of trials, there are a lot of unknowns such as patient recruitment, funding, successful readout of data and application to FDA/TGA, etc. Investor guesses is sometime within the first 6 months of 2024 and that is only a guess.
These are my notes, so if someone else was at the meeting and wants to correct or elaborate on my notes, please feel free to do so and my feelings will not be hurt.
Conclusion: I know we are all very frustrated with the slow pace that this is taking and the low share price and low volume. Management acknowledged our frustration and stated they are also frustrated with the low stock price because they are also stockholders. My impression is that by the next annual meeting, things will be significantly different. I also acknowledge that we have all thought this year after year. I've often said if making money in this stock was easy everybody would be doing it. However, this has been a very difficult investment for all of us and I believe in the long run it could very well be an investment of a lifetime. The Board Members believe PV-10 could be an industry disrupter and could completely change oncology. Not only do we have a great drug, but I believe we have good men on the board of directors. These thoughts are my opinion and based on years of being invested in PVCT, so take it for what it's worth.
I'm planning on going to the Annual Meeting on 6/21/23. Anyone else going? If so, several of us investors usually get together for lunch prior to the meeting if you are interested. Let me know and I'll give you the details.
I agree, great post!
Interesting to know, then I hope MP has a plan to get it over .01 and then upgraded to the OTCQB.
I'm thinking once MDCE changes their name and is upgraded from the Pinks to the OTCQB board, then we have a good chance of seeing this go up significantly. The question is when these two things are going to happen????
If anyone sees the commercials, please let us know if they look good and professional.
I'm hoping once the 1st Quarterly is posted and then potentially the upgrade from the Pinks to the OTCQB, more people will be interested in investing in the company. They obviously also need to change the company's name to something that matches what the company does. We need to be patient; hopefully good things are coming.
It will come soon, and soon may be here now. We will see sooner or later.
Shell Risk Designation has been removed. $MDCE
Everything MP has done is to build a real company that has real value. There is no reason a company with real revenue and assets should be worth .0025. His 2022 Annual Report has been filed and the Quarterly is due out in April. There is no reason this stock’s price shouldn’t be rising soon.
Let’s hope this week is the start of the rise of mdce! I can’t believe MP would just buy 5M shares if things weren’t about to take off. IMO
Remember that the Annual Report period ended on 31 Dec 22.
The other filing was the Annual Report.
https://www.otcmarkets.com/otcapi/company/financial-report/361244/content
Supplemental Disclosure for Change of Shell Status
Medical Care Technologies, Inc.
1910 S. Stapley Drive, Suite 221
Mesa, AZ 85204
480-645-0750
https://medcaretechinc.com
contact@medicaretechinco.com
SIC Code: 6719
Report Date: March 6, 2023
The goal of this disclosure is to provide information with respect to the company’s Change of Shell Status.
The Company was previously deemed to be a Shell Company and is changing its status as the Company
has determined that it no longer meets the definition of a Shell Company. The Effective Date of the change
in Shell Company Status is October 3, 2022, having commenced operations as further set forth below.
Medical Care Technologies Inc. Acquired Infinite Auctions on October 3, 2022. Infinite Auctions is an
online auction house that provides an online platform for memorabilia collectors and professional athletes
to consign and sell high valued collectibles in a secure online auction format.
As of December 31, 2022, MDCE reported Assets of $1,045,497 of which $11,797 are in Cash and
$1,045,497 are in Inventory. Prior to this time the Company was considered a “shell company” as defined
in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934.
The definition of a shell company as defined in Rule 405 under the Securities Act of 1933 as well as Release
33-8587, is whether the entity has no or nominal operations and no or nominal assets. Neither the release
nor the Act requires that a company meet both requirements of Rule 405 so as not to be considered a shell.
The Rule states:
The term shell company means a registrant . . . that has:
1. No or nominal operations; and
2. Either:
i. No or nominal assets;
ii. Assets consisting solely of cash and cash equivalents; or
iii. Assets consisting of any amount of cash and cash equivalents
and nominal other assets.
Additionally, the Securities and Exchange Commission has made itself clear within footnote 172 of
Release No. 33-8869 “indicating that Rule 144 (i)(1)(i) is not intended to capture a ‘startup company,’
or, in other words, a company with limited operating history, in the definition of a reporting or nonreporting shell company” because the company does not meet the conditions of having “no or nominal
operations.
Thus, the Company has more than nominal operations as demonstrated by its online auction platform
and has more than nominal assets consisting of cash and inventory that are used in the operation of its
business. Therefore, the Company is not currently a “shell company” as defined in Rule 405 of the
Securities Act of 1933 as well as SEC Release No. 33-8587 and footnote 172 of SEC Release No. 33
You would think making a public announcement on Twitter that announcements will now be vis PRs would indicate something significant to reveal. Hopefully tomorrow ????